Literature DB >> 9184377

Identification of genes coding for tumor antigens recognized by cytolytic T lymphocytes.

E De Plaen1, C Lurquin, B Lethé, P van der Bruggen, V Brichard, J C Renauld, P Coulie, A Van Pel, T Boon.   

Abstract

Strategies have been developed to characterize tumor antigens recognized by cytolytic T lymphocytes (CTL). We use a genetic approach based on the transfection of HLA genes and cDNA libraries in COS cells to isolate the gene producing the antigenic peptide. The tumor-specific expression of this gene can be evaluated by cDNA synthesis and quantitative PCR amplification. Transfection of fragments of the isolated gene allows the identification of the region encoding the antigenic peptide. Peptides are synthesized and tested for their ability to sensitize target cells to lysis by the CTL.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9184377     DOI: 10.1006/meth.1997.0462

Source DB:  PubMed          Journal:  Methods        ISSN: 1046-2023            Impact factor:   3.608


  8 in total

1.  Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele.

Authors:  S Gnjatic; Y Nagata; E Jager; E Stockert; S Shankara; B L Roberts; G P Mazzara; S Y Lee; P R Dunbar; B Dupont; V Cerundolo; G Ritter; Y T Chen; A Knuth; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

Review 2.  Adequate antigen availability: a key issue for novel approaches to tumor vaccination and tumor immunotherapy.

Authors:  Roberto S Accolla; Giovanna Tosi
Journal:  J Neuroimmune Pharmacol       Date:  2012-12-07       Impact factor: 4.147

3.  Theileria parva candidate vaccine antigens recognized by immune bovine cytotoxic T lymphocytes.

Authors:  Simon P Graham; Roger Pellé; Yoshikazu Honda; Duncan M Mwangi; Nyerhovwo J Tonukari; Mat Yamage; E Jane Glew; Etienne P de Villiers; Trushar Shah; Richard Bishop; Evelyne Abuya; Elias Awino; James Gachanja; Anthony E Luyai; Ferdinand Mbwika; Anthony M Muthiani; David M Ndegwa; Moses Njahira; John K Nyanjui; Fredrick O Onono; Julius Osaso; Rosemary M Saya; Claude Wildmann; Claire M Fraser; Ian Maudlin; Malcolm J Gardner; Subhash P Morzaria; Sheena Loosmore; Sarah C Gilbert; Jean-Christophe Audonnet; Pierre van der Bruggen; Vishvanath Nene; Evans L N Taracha
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-21       Impact factor: 11.205

Review 4.  Optimal MHC-II-restricted tumor antigen presentation to CD4+ T helper cells: the key issue for development of anti-tumor vaccines.

Authors:  Roberto S Accolla; Giovanna Tosi
Journal:  J Transl Med       Date:  2012-07-31       Impact factor: 5.531

5.  A new antigen recognized by cytolytic T lymphocytes on a human kidney tumor results from reverse strand transcription.

Authors:  B J Van Den Eynde; B Gaugler; M Probst-Kepper; L Michaux; O Devuyst; F Lorge; P Weynants; T Boon
Journal:  J Exp Med       Date:  1999-12-20       Impact factor: 14.307

6.  A novel strategy for the identification of antigens that are recognised by bovine MHC class I restricted cytotoxic T cells in a protozoan infection using reverse vaccinology.

Authors:  Simon P Graham; Yoshikazu Honda; Roger Pellé; Duncan M Mwangi; E Jane Glew; Etienne P de Villiers; Trushar Shah; Richard Bishop; Pierre van der Bruggen; Vishvanath Nene; Evans L N Taracha
Journal:  Immunome Res       Date:  2007-02-09

7.  Lack of evidence for MHC-unrestricted (atypical) recognition of mucin by mucinous pancreatic tumour-reactive T-cells.

Authors:  R S Selvan; T N Pappas; F E Ward
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

8.  HLA-E-restricted cross-recognition of allogeneic endothelial cells by CMV-associated CD8 T cells: a potential risk factor following transplantation.

Authors:  Mathilde Allard; Pierre Tonnerre; Steven Nedellec; Romain Oger; Alexis Morice; Yannick Guilloux; Elisabeth Houssaint; Béatrice Charreau; Nadine Gervois
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.